Metastasis-Free Survival Versus Treatment-Free Survival in Biochemically Recurrent Prostate Cancer: The EMBARK Trial

Overview

Journal J Clin Oncol

Specialty Oncology

Date 2024 May 16

PMID 38754067

Authors

David J Einstein

Meredith M Regan

Julia S Stevens

David F Mcdermott

Ravi A Madan

Affiliations

Soon will be listed here.

Abstract

What is most important to patients with BCR prostate cancer? Metastasis-free versus treatment-free survival.

Citing Articles

PSMA-PET/CT Findings in Patients With High-Risk Biochemically Recurrent Prostate Cancer With No Metastatic Disease by Conventional Imaging.

Holzgreve A, Armstrong W, Clark K, Benz M, Smith C, Djaileb L JAMA Netw Open. 2025; 8(1):e2452971.

PMID: 39752157 PMC: 11699533. DOI: 10.1001/jamanetworkopen.2024.52971.

References

Tombal B, Borre M, Rathenborg P, Werbrouck P, van Poppel H, Heidenreich A . Long-term Efficacy and Safety of Enzalutamide Monotherapy in Hormone-naïve Prostate Cancer: 1- and 2-Year Open-label Follow-up Results. Eur Urol. 2015; 68(5):787-94. DOI: 10.1016/j.eururo.2015.01.027. View

Perdona S, Autorino R, De Placido S, DArmiento M, Gallo A, Damiano R . Efficacy of tamoxifen and radiotherapy for prevention and treatment of gynaecomastia and breast pain caused by bicalutamide in prostate cancer: a randomised controlled trial. Lancet Oncol. 2005; 6(5):295-300. DOI: 10.1016/S1470-2045(05)70103-0. View

Lopes R, Higano C, Slovin S, Nelson A, Bigelow R, Sorensen P . Cardiovascular Safety of Degarelix Versus Leuprolide in Patients With Prostate Cancer: The Primary Results of the PRONOUNCE Randomized Trial. Circulation. 2021; 144(16):1295-1307. PMC: 9004319. DOI: 10.1161/CIRCULATIONAHA.121.056810. View

Sweeney C, Martin A, Stockler M, Begbie S, Chi K, Chowdhury S . Overall Survival of Men with Metachronous Metastatic Hormone-sensitive Prostate Cancer Treated with Enzalutamide and Androgen Deprivation Therapy. Eur Urol. 2021; 80(3):275-279. DOI: 10.1016/j.eururo.2021.05.016. View

Khalaf D, Annala M, Taavitsainen S, Finch D, Oja C, Vergidis J . Optimal sequencing of enzalutamide and abiraterone acetate plus prednisone in metastatic castration-resistant prostate cancer: a multicentre, randomised, open-label, phase 2, crossover trial. Lancet Oncol. 2019; 20(12):1730-1739. DOI: 10.1016/S1470-2045(19)30688-6. View

Regan M, Werner L, Rao S, Gupte-Singh K, Hodi F, Kirkwood J . Treatment-Free Survival: A Novel Outcome Measure of the Effects of Immune Checkpoint Inhibition-A Pooled Analysis of Patients With Advanced Melanoma. J Clin Oncol. 2019; 37(35):3350-3358. PMC: 6901280. DOI: 10.1200/JCO.19.00345. View

Duchesne G, Woo H, Bassett J, Bowe S, DEste C, Frydenberg M . Timing of androgen-deprivation therapy in patients with prostate cancer with a rising PSA (TROG 03.06 and VCOG PR 01-03 [TOAD]): a randomised, multicentre, non-blinded, phase 3 trial. Lancet Oncol. 2016; 17(6):727-737. DOI: 10.1016/S1470-2045(16)00107-8. View

Regan M, Jegede O, Mantia C, Powles T, Werner L, Motzer R . Treatment-free Survival after Immune Checkpoint Inhibitor Therapy versus Targeted Therapy for Advanced Renal Cell Carcinoma: 42-Month Results of the CheckMate 214 Trial. Clin Cancer Res. 2021; 27(24):6687-6695. PMC: 9357269. DOI: 10.1158/1078-0432.CCR-21-2283. View

Nguyen P, Alibhai S, Basaria S, DAmico A, Kantoff P, Keating N . Adverse effects of androgen deprivation therapy and strategies to mitigate them. Eur Urol. 2014; 67(5):825-36. DOI: 10.1016/j.eururo.2014.07.010. View

10.

Freedland S, de Almeida Luz M, De Giorgi U, Gleave M, Gotto G, Pieczonka C . Improved Outcomes with Enzalutamide in Biochemically Recurrent Prostate Cancer. N Engl J Med. 2023; 389(16):1453-1465. DOI: 10.1056/NEJMoa2303974. View

11.

Marshall C, Chen Y, Kuo C, Cullen J, Jiang J, Rosner I . Timing of Androgen Deprivation Treatment for Men with Biochemical Recurrent Prostate Cancer in the Context of Novel Therapies. J Urol. 2021; 206(3):623-629. PMC: 9774680. DOI: 10.1097/JU.0000000000001797. View

12.

Iacovelli R, Ciccarese C, Bria E, Romano M, Fantinel E, Bimbatti D . The Cardiovascular Toxicity of Abiraterone and Enzalutamide in Prostate Cancer. Clin Genitourin Cancer. 2018; 16(3):e645-e653. DOI: 10.1016/j.clgc.2017.12.007. View

13.

Einstein D, Aragon-Ching J, Karzai F, Madan R . Biochemically recurrent prostate cancer in the era of EMBARK and PSMA PET imaging: everything has changed, except the patients. Curr Opin Oncol. 2024; 36(3):164-168. DOI: 10.1097/CCO.0000000000001030. View

14.

Shore N, Saad F, Cookson M, George D, Saltzstein D, Tutrone R . Oral Relugolix for Androgen-Deprivation Therapy in Advanced Prostate Cancer. N Engl J Med. 2020; 382(23):2187-2196. DOI: 10.1056/NEJMoa2004325. View

15.

Xie W, Regan M, Buyse M, Halabi S, Kantoff P, Sartor O . Metastasis-Free Survival Is a Strong Surrogate of Overall Survival in Localized Prostate Cancer. J Clin Oncol. 2017; 35(27):3097-3104. PMC: 5652387. DOI: 10.1200/JCO.2017.73.9987. View

16.

Deek M, Van der Eecken K, Sutera P, Deek R, Fonteyne V, Mendes A . Long-Term Outcomes and Genetic Predictors of Response to Metastasis-Directed Therapy Versus Observation in Oligometastatic Prostate Cancer: Analysis of STOMP and ORIOLE Trials. J Clin Oncol. 2022; 40(29):3377-3382. PMC: 10166371. DOI: 10.1200/JCO.22.00644. View